Related Experiment Video
Updated: Jun 6, 2025

Longitudinal Evaluation of Mouse Hind Limb Bone Loss After Spinal Cord Injury using Novel, in vivo, Methodology
Published on: December 7, 2011
iPSCs-derived iMSCs prevent osteoporotic bone loss and affect bone metabolites in ovariectomized mice
Wei-Zhou Wang1,2, Yang-Hao Wang3, Sha-Sha Bao4
1Yunnan Provincial Key Laboratory of Public Health and Biosafety and School of Public Health, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
Abstract:
Osteoporosis is a metabolic bone disease that seriously jeopardizes the health of middle-aged and elderly people. Mesenchymal stem cell-based transplantation for osteoporosis is a promising new therapeutic strategy. Induced mesenchymal stem cells (iMSCs) are a new option for stem cell transplantation therapy. Acquired mouse skin fibroblasts were transduced and reprogrammed into induced pluripotent cells and further induced to differentiate into iMSCs. The iMSCs were tested for pluripotency markers, trilineage differentiation ability, cell surface molecular marker tests, and gene expression patterns. The iMSCs were injected into the tail vein of mice by tail vein injection, and the distribution of cells in various organs was observed. The effect of iMSCs on the bone mass of mice was detected after injection into the mouse osteoporosis model. The effects of iMSCs infusion on metabolites in femoral tissue and peripheral blood plasma were detected based on LC-MS untargeted metabolomics. iMSCs have similar morphology, immunophenotype, in vitro differentiation potential, and gene expression patterns as mesenchymal stem cells. The iMSCs were heavily distributed in the lungs after infusion and gradually decreased over time. The iMSCs in the femoral bone marrow cavity gradually increased with time. iMSCs infusion significantly avoided bone loss due to oophorectomy. The results of untargeted metabolomics suggest that amino acid and lipid metabolic pathways are key factors involved in iMSCs bone protection and prevention of osteoporosis formation. iMSCs obtained by reprogramming-induced differentiation had cellular properties similar to those of bone marrow mesenchymal stem cells. The iMSCs could promote the remodelling of bone structure in ovariectomy-induced osteoporotic mice and affect the changes of several key metabolites in bone and peripheral blood. Some of these metabolites can serve as potential biomarkers and therapeutic targets for iMSCs intervention in osteoporosis. Investigating the effects of iMSCs on osteoporosis and the influence of metabolic pathways will provide new ideas and methods for the clinical treatment of osteoporosis.
Insights
Induced mesenchymal stem cells (iMSCs) show promise for treating osteoporosis by improving bone mass and remodeling. These cells influence amino acid and lipid metabolism, offering potential therapeutic targets for bone disease.
Area of Science:
- Regenerative Medicine
- Stem Cell Biology
- Metabolic Bone Disease
Background:
- Osteoporosis is a significant health concern for middle-aged and elderly populations.
- Mesenchymal stem cell transplantation is a potential therapeutic strategy for osteoporosis.
- Induced mesenchymal stem cells (iMSCs) offer a novel cell source for transplantation therapy.
Purpose of the Study:
- To investigate the characteristics and therapeutic potential of iMSCs in an osteoporosis model.
- To evaluate the biodistribution and bone-protective effects of iMSCs.
- To explore the metabolic changes associated with iMSCs treatment in osteoporosis.
Main Methods:
- Fibroblasts were reprogrammed into iMSCs, which were characterized for pluripotency and differentiation.
- iMSCs were administered via tail vein injection into an ovariectomy-induced osteoporosis mouse model.
- Cell distribution, bone mass, and metabolic profiles (LC-MS untargeted metabolomics) were analyzed.
Main Results:
- iMSCs exhibited properties similar to bone marrow mesenchymal stem cells, including morphology, immunophenotype, and differentiation potential.
- iMSCs were detected in bone marrow over time, and their infusion significantly prevented bone loss.
- Metabolomic analysis revealed that amino acid and lipid metabolic pathways are crucial for iMSCs' bone-protective effects.
Conclusions:
- iMSCs are a viable cell source for osteoporosis therapy, demonstrating bone remodeling capabilities.
- iMSCs influence key metabolites in bone and blood, suggesting potential biomarkers and therapeutic targets.
- Understanding iMSCs' impact on metabolic pathways offers new avenues for osteoporosis treatment.

